

Vivianne C G Tjan-Heijnen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4280088/publications.pdf>

Version: 2024-02-01

77
papers

2,768
citations

304368

22
h-index

205818

48
g-index

77
all docs

77
docs citations

77
times ranked

5633
citing authors

#	ARTICLE	IF	CITATIONS
1	The implementation of CDK 4/6 inhibitors and its impact on treatment choices in HR ⁺ /HER2 ⁺ advanced breast cancer patients: A study of the Dutch SONABRE Registry. <i>International Journal of Cancer</i> , 2022, 150, 124-131.	2.3	6
2	The initial hormone receptor/HER2 subtype is the main determinant of subtype discordance in advanced breast cancer: a study of the SONABRE registry. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 331.	1.1	3
3	Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2022, 61, 619-624.	0.8	0
4	Abstract P3-03-21: Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: What do they mean?. <i>Cancer Research</i> , 2022, 82, P3-03-21-P3-03-21.	0.4	0
5	Adjuvant and first-line palliative chemotherapy regimens in patients diagnosed with periampullary cancer: a short report from a nationwide registry. <i>Acta Oncologica</i> , 2022, 61, 591-596.	0.8	2
6	Noninvasive Prenatal Test Results Indicative of Maternal Malignancies: A Nationwide Genetic and Clinical Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 2426-2435.	0.8	23
7	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
8	Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor ⁺ Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2934-2945.	0.8	6
9	Associations of hospital volume and hospital competition with short-term, middle-term and long-term patient outcomes after breast cancer surgery: a retrospective population-based study. <i>BMJ Open</i> , 2022, 12, e057301.	0.8	0
10	Frequency and diagnostic outcome of bilateral recall at screening mammography. <i>International Journal of Cancer</i> , 2021, 148, 48-56.	2.3	1
11	Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 571-581.	1.1	5
12	Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 64.	6.9	61
13	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.	0.5	5
14	Evaluation of the Khorana, PROTECHT, and 5â€šNP scores for prediction of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2974-2983.	1.9	14
15	Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 245-254.	1.1	3
16	Additional Breast Cancer Detection at Digital Screening Mammography through Quality Assurance Sessions between Technologists and Radiologists. <i>Radiology</i> , 2020, 294, 509-517.	3.6	6
17	The influence on quality of life of intermittent scheduling in first- and second-line chemotherapy of patients with HER2-negative advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 677-685.	1.1	1
18	Pervasive chromosomal instability and karyotype order in tumour evolution. <i>Nature</i> , 2020, 587, 126-132.	13.7	221

#	ARTICLE	IF	CITATIONS
19	Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. <i>Quality of Life Research</i> , 2020, 29, 3363-3374.	1.5	11
20	Delayed breast cancer diagnosis after repeated recall at biennial screening mammography: an observational follow-up study from the Netherlands. <i>British Journal of Cancer</i> , 2020, 123, 325-332.	2.9	8
21	The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 102988.	2.0	25
22	An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. <i>Acta Oncologica</i> , 2020, 59, 1123-1130.	0.8	3
23	Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 675-685.	1.1	4
24	Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer. <i>Acta Oncologica</i> , 2020, 59, 713-722.	0.8	5
25	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	3.4	17
26	Recall and Outcome of Screen-detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. <i>Radiology</i> , 2020, 294, 528-537.	3.6	9
27	Preserving fertility in young women undergoing chemotherapy for early breast cancer; the Maastricht experience. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 77-86.	1.1	16
28	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. <i>Acta Oncologica</i> , 2020, 59, 895-903.	0.8	10
29	Abstract P1-19-34: The role of hormone receptor (HR) status on initial treatment choices and outcomes for human epidermal growth factor receptor (HER)-2 positive advanced breast cancer: A study of the southeast Netherlands advanced breast cancer (SONABRE) registry. , 2020, , .		1
30	Characteristics of screen-detected cancers following concordant or discordant recalls at blinded double reading in biennial digital screening mammography. <i>European Radiology</i> , 2019, 29, 337-344.	2.3	3
31	Population-based study of the effect of preoperative breast MRI on the surgical management of ductal carcinoma <i>in situ</i> . <i>British Journal of Surgery</i> , 2019, 106, 1488-1494.	0.1	15
32	Predicting the extent of nodal involvement for node positive breast cancer patients: Development and validation of a novel tool. <i>Journal of Surgical Oncology</i> , 2019, 120, 578-586.	0.8	11
33	The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study. <i>Diagnostic and Prognostic Research</i> , 2019, 3, 20.	0.8	1
34	Trends in Overall Survival and Treatment Patterns in Two Large Population-Based Cohorts of Patients with Breast and Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1239.	1.7	9
35	The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. <i>Nature Genetics</i> , 2019, 51, 1450-1458.	9.4	250
36	Utility of diagnostic breast excision biopsies during two decades of screening mammography. <i>Breast</i> , 2019, 46, 157-162.	0.9	6

#	ARTICLE	IF	CITATIONS
37	Trends in frequency and outcome of high-risk breast lesions at core needle biopsy in women recalled at biennial screening mammography, a multiinstitutional study. <i>International Journal of Cancer</i> , 2019, 145, 2720-2727.	2.3	10
38	Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. <i>International Journal of Cancer</i> , 2019, 145, 1325-1333.	2.3	8
39	Pan-cancer whole-genome analyses of metastatic solid tumours. <i>Nature</i> , 2019, 575, 210-216.	13.7	722
40	Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure. <i>International Journal of Cancer</i> , 2019, 145, 274-283.	2.3	7
41	Trends in treatment and overall survival among patients with proximal esophageal cancer. <i>World Journal of Gastroenterology</i> , 2019, 25, 6835-6846.	1.4	13
42	Incidence and tumour characteristics of bilateral and unilateral interval breast cancers at screening mammography. <i>Breast</i> , 2018, 38, 101-106.	0.9	8
43	Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 26.	1.3	44
44	Moving Breast Cancer Therapy up a Notch. <i>Frontiers in Oncology</i> , 2018, 8, 518.	1.3	63
45	Frequency and characteristics of additionally detected ipsilateral breast lesions following recall at screening mammography. <i>Breast</i> , 2018, 42, 94-101.	0.9	0
46	The Lymph Node and the Metastasis. <i>New England Journal of Medicine</i> , 2018, 378, 2045-2046.	13.9	19
47	Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers. <i>British Journal of Cancer</i> , 2018, 119, 357-363.	2.9	22
48	Impact of the second reader on screening outcome at blinded double reading of digital screening mammograms. <i>British Journal of Cancer</i> , 2018, 119, 503-507.	2.9	20
49	Incorporation of the technologist's opinion for arbitration of discrepant assessments among radiologists at screening mammography. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 143-149.	1.1	2
50	Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). <i>Breast Cancer Research and Treatment</i> , 2018, 172, 413-423.	1.1	13
51	Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth. <i>Journal of Pathology</i> , 2018, 246, 447-458.	2.1	67
52	Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 353-364.	1.1	39
53	What to Do with Non-visualized Sentinel Nodes? A Dutch Nationwide Survey Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2155-2160.	0.7	4
54	Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 133-138.	1.1	12

#	ARTICLE	IF	CITATIONS
55	Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	19
56	Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: The national NABON Breast Cancer Audit. <i>Journal of Surgical Oncology</i> , 2017, 115, 243-249.	0.8	62
57	Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1502-1511.	5.1	119
58	Interval breast cancer characteristics before, during and after the transition from screen-film to full-field digital screening mammography. <i>BMC Cancer</i> , 2017, 17, 315.	1.1	10
59	Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 555-563.	1.1	13
60	Intestinal-type sinonasal adenocarcinomas: The road to molecular diagnosis and personalized treatment. <i>Head and Neck</i> , 2016, 38, 1564-1570.	0.9	35
61	Type and Extent of Surgery for Screen-Detected and Interval Cancers at Blinded Versus Nonblinded Double-Reading in a Population-Based Screening Mammography Program. <i>Annals of Surgical Oncology</i> , 2016, 23, 3822-3830.	0.7	3
62	Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 471-483.	1.1	44
63	Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncologist</i> , 2016, 21, 555-562.	1.9	35
64	A Dutch Prediction Tool to Assess the Risk of Additional Axillary Non-Sentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 123-130.	1.1	16
65	The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. <i>Oncotarget</i> , 2016, 7, 29412-29419.	0.8	11
66	Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium. <i>Oncologist</i> , 2015, 20, 856-863.	1.9	31
67	Loneliness in patients with cancer: the first year after cancer diagnosis. <i>Psycho-Oncology</i> , 2015, 24, 1521-1528.	1.0	33
68	The relation between depression, coping and health locus of control: differences between older and younger patients, with and without cancer. <i>Psycho-Oncology</i> , 2015, 24, 950-957.	1.0	54
69	Breast cancer diagnosis and death in the Netherlands: a changing burden. <i>European Journal of Public Health</i> , 2015, 25, 320-324.	0.1	34
70	Formalin-fixed, paraffin-embedded (FFPE) tissue epigenomics using Infinium HumanMethylation450 BeadChip assays. <i>Laboratory Investigation</i> , 2015, 95, 833-842.	1.7	40
71	CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. <i>Oncotarget</i> , 2015, 6, 19634-19646.	0.8	53
72	Maastricht Delphi Consensus on Event Definitions for Classification of Recurrence in Breast Cancer Research. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	73

#	ARTICLE	IF	CITATIONS
73	Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 507-514.	1.1	192
74	Prognostic Impact of Isolated Tumor Cells and Micrometastases in Axillary Lymph Nodes of Breast Cancer Patients. <i>Breast Disease</i> , 2010, 31, 107-113.	0.4	10
75	The Breast Cancer Sentinel Node Dilemma: What to do with Isolated Tumor Cells and Micrometastases?. <i>Breast Disease</i> , 2010, 31, 61-63.	0.4	0
76	Micrometastases and Isolated Tumor Cells in Breast Cancer Are Indeed Associated With Poorer Outcome. <i>Journal of Clinical Oncology</i> , 2010, 28, e140-e140.	0.8	10
77	Modeling the Cost Effectiveness of Secondary Febrile Neutropenia Prophylaxis During Standard-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 290-296.	0.8	25